International Journal of Hematology

, Volume 95, Issue 5, pp 585–587 | Cite as

Bilateral subdural hemorrhage as a serious adverse event of dasatinib in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia

  • Ho-Young Yhim
  • Hee Sun Kim
  • Na-Ri Lee
  • Eun-Kee Song
  • Jae-Yong Kwak
  • Chang-Yeol Yim
Letter to the Editor

Notes

Acknowledgments

This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (0620220-1).

Conflict of interest

The authors declare that there are no conflicts of interest.

References

  1. 1.
    Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007;110:2309–15.PubMedCrossRefGoogle Scholar
  2. 2.
    Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531–41.PubMedCrossRefGoogle Scholar
  3. 3.
    Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109:5143–50.PubMedCrossRefGoogle Scholar
  4. 4.
    Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–70.PubMedCrossRefGoogle Scholar
  5. 5.
    Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658–61.PubMedCrossRefGoogle Scholar
  6. 6.
    Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009;113:6322–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res. 2008;14:352–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Quintas-Cardama A, Kantarjian H, Ravandi F, et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer. 2009;115:2482–90.PubMedCrossRefGoogle Scholar
  9. 9.
    Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997;277:242–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009;114:261–3.PubMedCrossRefGoogle Scholar
  11. 11.
    Gratacap MP, Martin V, Valera MC, et al. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood. 2009;114:1884–92.PubMedCrossRefGoogle Scholar
  12. 12.
    Christopher LJ, Cui D, Wu C, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008;36:1357–64.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2012

Authors and Affiliations

  • Ho-Young Yhim
    • 1
  • Hee Sun Kim
    • 2
  • Na-Ri Lee
    • 1
    • 3
  • Eun-Kee Song
    • 1
    • 3
  • Jae-Yong Kwak
    • 1
    • 3
  • Chang-Yeol Yim
    • 1
    • 3
  1. 1.Division of Hematology/Oncology, Department of Internal MedicineChonbuk National University Medical SchoolJeonjuKorea
  2. 2.Department of NursingWoosuk UniversityWanjuKorea
  3. 3.Advanced Research Cancer CenterChonbuk National University Medical SchoolJeonjuKorea

Personalised recommendations